{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:06:56Z","timestamp":1790784416937,"version":"4.1.0"},"reference-count":33,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Prostate cancer (PCa) represents one of the leading causes of cancer-related mortality among men. The efficacy of its treatment is often compromised by chemotherapeutic toxicity and multidrug resistance, underscoring the urgent need to develop efficient and low-toxicity alternative therapeutic strategies. Homoharringtonine (HHT), a bioactive compound, has demonstrated clinical anticancer efficacy in hematologic malignancies. However, its role and underlying mechanisms in prostate cancer remain largely unclear. This study provides evidence that HHT suppresses prostate cancer cell proliferation and promotes cell cycle arrest by modulating the TNF\/NF-\u03baB and MAPK signaling pathways, indicating its potential as a promising natural drug candidate for PCa treatment.<\/jats:p>","DOI":"10.3390\/cells15191788","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:20:59Z","timestamp":1790781659000},"page":"1788","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Homoharringtonine Suppresses Prostate Cancer Progression Through Modulation of the TNF\/NF-\u03baB and MAPK Signaling Pathways"],"prefix":"10.3390","volume":"15","author":[{"given":"Yuzhong","family":"Chen","sequence":"first","affiliation":[{"name":"NHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Pharmacy School of Pharmaceutical Sciences Fudan University, Shanghai 200237, China"},{"name":"Department of Pharmacology & Toxicology, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"software","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0452-4461","authenticated-orcid":false,"given":"Sisi","family":"Huang","sequence":"additional","affiliation":[{"name":"NHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Pharmacy School of Pharmaceutical Sciences Fudan University, Shanghai 200237, China"},{"name":"Department of Pharmacology & Toxicology, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"}]},{"given":"Dongyan","family":"Huang","sequence":"additional","affiliation":[{"name":"NHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Pharmacy School of Pharmaceutical Sciences Fudan University, Shanghai 200237, China"},{"name":"Department of Pharmacology & Toxicology, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Yangtao","family":"Jin","sequence":"additional","affiliation":[{"name":"NHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Pharmacy School of Pharmaceutical Sciences Fudan University, Shanghai 200237, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Congcong","family":"Shao","sequence":"additional","affiliation":[{"name":"NHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Pharmacy School of Pharmaceutical Sciences Fudan University, Shanghai 200237, China"},{"name":"Department of Pharmacology & Toxicology, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"}]},{"given":"Xin","family":"Su","sequence":"additional","affiliation":[{"name":"NHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Pharmacy School of Pharmaceutical Sciences Fudan University, Shanghai 200237, China"},{"name":"Department of Pharmacology & Toxicology, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Rongfu","family":"Yang","sequence":"additional","affiliation":[{"name":"NHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Pharmacy School of Pharmaceutical Sciences Fudan University, Shanghai 200237, China"},{"name":"Department of Pharmacology & Toxicology, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"}]},{"given":"Juan","family":"Jiang","sequence":"additional","affiliation":[{"name":"NHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Pharmacy School of Pharmaceutical Sciences Fudan University, Shanghai 200237, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"}]},{"given":"Jianhui","family":"Wu","sequence":"additional","affiliation":[{"name":"NHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Pharmacy School of Pharmaceutical Sciences Fudan University, Shanghai 200237, China"},{"name":"Department of Pharmacology & Toxicology, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/jama.2025.0228","article-title":"Prostate Cancer: A Review","volume":"333","author":"Raychaudhuri","year":"2025","journal-title":"Jama"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: Planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","article-title":"Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates","volume":"77","author":"Culp","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1146\/annurev-med-051517-011947","article-title":"Treatment of Advanced Prostate Cancer","volume":"70","author":"Teo","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1038\/modpathol.2017.158","article-title":"Treatment effects in prostate cancer","volume":"31","author":"Evans","year":"2018","journal-title":"Mod. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/cpt.256","article-title":"Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance","volume":"98","author":"Crona","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s12032-016-0793-1","article-title":"Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer","volume":"33","author":"Schweizer","year":"2016","journal-title":"Med. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.juro.2018.07.090","article-title":"Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018","volume":"200","author":"Lowrance","year":"2018","journal-title":"J. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Wu, L., Qiu, J., Hong, Z., Wang, Q., Li, Q., and Zhou, W. (2025). Unravelling targeted therapy in prostate cancer: From molecular mechanisms to translational opportunities. Front. Cell Dev. Biol., 13.","DOI":"10.3389\/fcell.2025.1685857"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/21681805.2021.1936626","article-title":"Real world treatment utilization patterns in patients with castration-resistant prostate cancer","volume":"55","author":"Vigneswaran","year":"2021","journal-title":"Scand. J. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1756-8722-7-2","article-title":"Homoharringtonine and omacetaxine for myeloid hematological malignancies","volume":"7","author":"Wang","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/0014-5793(89)81546-7","article-title":"Alkaloid homoharringtonine inhibits polypeptide chain elongation on human ribosomes on the step of peptide bond formation","volume":"257","author":"Tujebajeva","year":"1989","journal-title":"FEBS Lett."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Wang, W., He, L., Lin, T., Xiang, F., Wu, Y., Zhou, F., and He, Y. (2025). Homoharringtonine: Mechanisms, clinical applications and research progress. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1522273"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"995","DOI":"10.7150\/ijbs.44907","article-title":"Homoharringtonine inhibited breast cancer cells growth via miR-18a-3p\/AKT\/mTOR signaling pathway","volume":"17","author":"Wang","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"110960","DOI":"10.1016\/j.fct.2019.110960","article-title":"Homoharringtonine suppresses LoVo cell growth by inhibiting EphB4 and the PI3K\/AKT and MAPK\/EKR1\/2 signaling pathways","volume":"136","author":"Shi","year":"2020","journal-title":"Food Chem. Toxicol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3441357","DOI":"10.1155\/2022\/3441357","article-title":"Homoharringtonine Attenuates Dextran Sulfate Sodium-Induced Colitis by Inhibiting NF-\u03baB Signaling","volume":"2022","author":"Liu","year":"2022","journal-title":"Mediat. Inflamm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"eadm7098","DOI":"10.1126\/sciadv.adm7098","article-title":"Identification of an anaplastic subtype of prostate cancer amenable to therapies targeting SP1 or translation elongation","volume":"10","author":"Zou","year":"2024","journal-title":"Sci. Adv."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Trembley, J.H., Kren, B.T., Abedin, M.J., Shaughnessy, D.P., Li, Y., Dehm, S.M., and Ahmed, K. (2019). CK2 Pro-Survival Role in Prostate Cancer Is Mediated via Maintenance and Promotion of Androgen Receptor and NF\u03baB p65 Expression. Pharmaceuticals, 12.","DOI":"10.3390\/ph12020089"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.cytogfr.2008.01.006","article-title":"IkappaB kinase beta (IKKbeta\/IKK2\/IKBKB)--a key molecule in signaling to the transcription factor NF-kappaB","volume":"19","author":"Schmid","year":"2008","journal-title":"Cytokine Growth Factor. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/cr.2011.13","article-title":"NF-\u03baB in immunobiology","volume":"21","author":"Hayden","year":"2011","journal-title":"Cell Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/ng.3459","article-title":"Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease","volume":"48","author":"Zhou","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.bbamcr.2007.03.010","article-title":"p38 MAP-kinases pathway regulation, function and role in human diseases","volume":"1773","author":"Cuenda","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/jnci\/89.17.1260","article-title":"Changing views of the role of matrix metalloproteinases in metastasis","volume":"89","author":"Chambers","year":"1997","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.canlet.2016.10.008","article-title":"Targeting p38 MAP kinase signaling in cancer through post-translational modifications","volume":"384","author":"Zou","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1158\/0008-5472.CAN-15-0173","article-title":"The Stress Kinase p38\u03b1 as a Target for Cancer Therapy","volume":"75","author":"Igea","year":"2015","journal-title":"Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/sj.cr.7290257","article-title":"Activation and signaling of the p38 MAP kinase pathway","volume":"15","author":"Zarubin","year":"2005","journal-title":"Cell Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1042\/BJ20100323","article-title":"Mechanisms and functions of p38 MAPK signalling","volume":"429","author":"Cuadrado","year":"2010","journal-title":"Biochem. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11060-012-0875-7","article-title":"p38 MAPK inhibitors attenuate pro-inflammatory cytokine production and the invasiveness of human U251 glioblastoma cells","volume":"109","author":"Yeung","year":"2012","journal-title":"J. Neurooncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.4049\/jimmunol.1602059","article-title":"Novel Noncatalytic Substrate-Selective p38\u03b1-Specific MAPK Inhibitors with Endothelial-Stabilizing and Anti-Inflammatory Activity","volume":"198","author":"Shah","year":"2017","journal-title":"J. Immunol."},{"key":"ref_30","first-page":"cm1","article-title":"Interleukin-1 (IL-1) pathway","volume":"3","author":"Weber","year":"2010","journal-title":"Sci. Signal"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/pros.20960","article-title":"Unique patterns of molecular profiling between human prostate cancer LNCaP and PC-3 cells","volume":"69","author":"Dozmorov","year":"2009","journal-title":"Prostate"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Robert, F., Carrier, M., Rawe, S., Chen, S., Lowe, S., and Pelletier, J. (2009). Altering chemosensitivity by modulating translation elongation. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0005428"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41467-023-35880-y","article-title":"CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer","volume":"14","author":"Tsujino","year":"2023","journal-title":"Nat. Commun."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/19\/1788\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:23:50Z","timestamp":1790781830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/19\/1788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":33,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["cells15191788"],"URL":"https:\/\/doi.org\/10.3390\/cells15191788","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]}}}